LG 50042

1. Andreassen KV, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA, Henriksen K. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. Am J Physiol Endocrinol Metab. 2014 Jul 1;307(1):E24-33. doi: 10.1152/ajpendo.00121.2014. Epub 2014 May 6. PubMed PMID: 24801386. 2. Hjuler ST, Andreassen KV, Gydesen S, Karsdal MA, Henriksen K. KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration. Eur J Pharmacol. 2015 Sep 5;762:229-38. doi: 10.1016/j.ejphar.2015.05.051. Epub 2015 May 28. PubMed PMID: 26027795. 3. Arakawa K, Maehara S, Yuge N, Ishikawa M, Miyazaki Y, Naba H, Kato Y, Nakao K. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidi n-1-yl)pyrimidin-4-yl)morpholine] in rats: potential for the treatment of schizophrenia. Pharmacol Res Perspect. 2016 Jun 10;4(4):e00241. doi: 10.1002/prp2.241. eCollection 2016 Aug. PubMed PMID: 28116094; PubMed Central PMCID: PMC5242175. 4. Miyake T, Honma Y, Urano T, Kato N, Suzumiya J. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells. Int J Oncol. 2015 Jul;47(1):315-24. doi: 10.3892/ijo.2015.2979. Epub 2015 Apr 30. PubMed PMID: 25936828.